Empatab M 5 mg+500 mg (Tablet)

Unit Price: ৳ 15.00 (3 x 10: ৳ 450.00)
Strip Price: ৳ 150.00

Medicine Details

Category Details
Generic Empagliflozin metformin hydrochloride
Company Incepta pharmaceuticals ltd

Title

  • Empatab M Tablet

Categories

  • Diabetes Medicine
  • Medication

Description

  • Recommended starting dose based on current drug regimen
  • Maximum recommended daily dose of Metformin Hydrochloride is 2000 mg
  • Maximum recommended daily dose of Empagliflozin is 25 mg
  • Individualized dosage based on effectiveness and tolerability
  • Twice daily administration with meals
  • Extended-release formulations available
  • Renal function assessment before use
  • Contraindicated in patients with eGFR below 45 mL/min/1.73 m^2
  • Not recommended for pediatric patients under 18 years of age
  • Increased urine volume and frequency of voids when co-administered with diuretics
  • Risk for hypoglycemia when co-administered with insulin or insulin secretagogues
  • Monitoring glycemic control with urine glucose tests not recommended
  • Increased risk of lactic acidosis when co-administered with carbonic anhydrase inhibitors
  • Possible drug interactions affecting glycemic control
  • Alcohol can potentiate the effect of Metformin on lactate metabolism
  • Contraindications for specific health conditions

Indications

  • Adjunct treatment for adults with type 2 diabetes mellitus
  • Insufficiently controlled patients on Metformin
  • Combination therapy in patients insufficiently controlled with Metformin and other medicinal products for diabetes
  • Treatment of patients already being treated with the combination of Empagliflozin and Metformin as separate tablets

Pharmacology

  • Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2)
  • Reduces renal reabsorption of filtered glucose
  • Lowers the renal threshold for glucose
  • Increases urinary glucose excretion
  • Biguanide type oral antihyperglycemic drug
  • Lowers basal and postprandial plasma glucose
  • Does not produce hypoglycemia
  • Decreases hepatic glucose production
  • Decreases intestinal absorption of glucose
  • Improves insulin sensitivity

Interaction

  • Contraindications for diuretics, insulin, and other drugs affecting glycemic control
  • Increased risk of volume depletion, hypoglycemia, and lactic acidosis with specific drug interactions

Dosage & Administration

  • Individualized dosage based on effectiveness and tolerability
  • Dose escalation should be gradual to reduce gastrointestinal side effects
  • Extended-release formulations available for once daily administration
  • Assessment of renal function before initiation
  • Recommended starting dose based on current drug regimen
  • Contraindicated in patients with eGFR below 45 mL/min/1.73 m^2
  • Not recommended for pediatric patients under 18 years of age

Contraindications

  • Hypersensitivity to Empagliflozin and Metformin
  • Acute metabolic acidosis
  • Diabetic pre-coma
  • Severe renal failure (GFR <30 ml/min)
  • Conditions affecting renal function or tissue oxygenation
  • Hepatic impairment
  • Acute alcohol intoxication
  • Alcoholism

Side Effects

  • Common and rare adverse reactions associated with Empagliflozin
  • Common adverse reactions associated with Metformin
  • Increased risk of hypoglycemia, urinary tract infections, and genital infections
  • Important adverse reactions to monitor

Pregnancy & Lactation

  • Potential risk to fetus in second and third trimesters
  • Not recommended during breastfeeding

Precautions & Warnings

  • Lactic acidosis
  • Hypotension
  • Ketoacidosis
  • Acute kidney injury & impairment in renal function
  • Increased risk for urinary tract infections and genital mycotic infections
  • Hypoglycemia
  • Vitamin B12 Deficiency
  • Increased LDL-C
  • No conclusive evidence of macrovascular risk reduction

Overdose Effects

  • No toxicity observed at high single or multiple doses in controlled studies
  • Treatment for lactic acidosis is a medical emergency
  • Haemodialysis for removing lactate and Metformin

Therapeutic Class

  • Oral hypoglycemic preparations

Storage Conditions

  • Keep below 30°C temperature
  • Protected from light & moisture
  • Keep out of the reach of children

Related Brands